"A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF Episodes"

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 3, 2017

Primary Completion Date

December 21, 2017

Study Completion Date

December 21, 2017

Conditions
Parkinson's DiseaseOff Episodes of Parkinson Disease
Interventions
DRUG

APL-130277

APL-130277 single dose

DRUG

Placebo

Placebo single dose

DRUG

Moxifloxacin

moxifloxacin 400mg single dose

Trial Locations (15)

30331

Atlanta Center for Medical Research, Atlanta

32806

Bioclinica Reserach, Orlando

33009

MD Clinical, Hallandale

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

36057

Casa di Cura villa Margherita (Neurologia), Arcugnano

48334

QUEST Research Institute, Farmington Hills

70810

The NeuroMedical Center, PC, Baton Rouge

72205

Clinical Trials, Inc., Little Rock

78681

Central Texas Neurology Consultants, Round Rock

85258

Movement Disorders Center of Arizona, Scottsdale

92708

The Parkinson's and Movement Disorder Institute, Fountain Valley

03043

Centro Ricerche San Raffaele, Cassino

Unknown

Agine Research Center, University Foundahon Chica-Pescara, Behavioral Neurology and Movement Disorders Unit, Chieti

00133

Neurologia, Policlinico Tor Vergata, Rome

00163

IRCCS San Raffaele Pisana,Clinical Trial Center, Rome

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT03187301 - "A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF Episodes" | Biotech Hunter | Biotech Hunter